益生菌补充剂用于改善糖尿病前期患者的葡萄糖脂质参数:随机试验的系统审查和元分析
Karunia Valeriani Japar1, Timotius Ivan Hariyanto2, Damian Vidana Hamzah3
1Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, 15811, Indonesia.
Probiotics and antimicrobial proteins
|January 13, 2025
概括
益生菌补充剂可能有助于降低血红蛋白A1c (HbA1c) 在糖尿病前期患者. 这次元分析发现益生菌对改善血糖控制而安全有效,而不会影响其他关键健康标志物.
科学领域:
- 代谢健康 代谢健康
- 肠道微生物组研究研究
- 临床营养学 临床营养学
背景情况:
- 糖尿病前期显著增加患2型糖尿病 (T2DM) 的风险.
- 新出现的证据表明,肠道微生物组在胰岛素耐药性发展中起着作用.
- 有效的干预措施对于管理糖尿病前期和预防T2DM进展至关重要.
研究的目的:
- 评估益生菌补充剂对糖尿病前期患者的疗效和安全性.
- 综合了关于益生菌和糖尿病前期的随机临床试验 (RCT) 的发现.
- 评估益生菌对血糖控制和其他代谢标记物的影响.
主要方法:
- 在主要数据库 (Cochrane Library,Medline,Scopus,ClinicalTrials.gov) 进行了系统的文献搜索,截至2024年9月12日.
- 包括随机临床试验 (RCT),调查益生菌对糖尿病前期患者的影响.
- 使用随机效应模型分析结果的平均差异 (MD).
主要成果:
- 八项RCT的元分析显示,益生菌补充剂导致血红蛋白A1c (HbA1c) 的统计学显著降低 (MD -0.07%).
- 在益生菌和安慰剂组之间没有观察到总胆固醇,LDL-C,HDL-C,甘油三 (TG) 或体重指数 (BMI) 的显著差异.
- 益生菌和安慰剂组之间的不良事件 (AEs) 的发生率是可比的,这表明了有利的安全性.
结论:
- 益生菌补充剂在改善糖尿病前期患者的血糖指标,特别是HbA1c方面表现出有效性.
- 益生菌似乎是糖尿病前期管理的安全干预措施,不显著增加不良事件.
- 进一步的研究可能会探索特定的益生菌菌株及其对糖尿病前期人口代谢健康的长期影响.
相关概念视频
Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
148
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
148
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
Dipeptidyl Peptidase 4 Inhibitors
165
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
Hypoglycemia and Glucagon
150
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
150
Hormones Regulating Blood Glucose
3.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.0K


